Department of Health
and Human Services (HHS)
and Human Services (HHS)
August 24, 2020
NOT-HG-20-013 - Notice of Change: Emphasizing an Opportunity for New Institutional Applicants in Response to PAR-19-204 Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
PAR-19-204 - Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
National Human Genome Research Institute (NHGRI)
As part of the Centers of Excellence in Genomic Sciences (CEGS) Funding Opportunity Announcement cited above, NHGRI will provide new support for high-quality applications from institutions that have not previously been funded under the CEGS program (see Related Announcements). This change is intended to be responsive to language in the US FY2020 budget to establish “Emerging Centers of Excellence in Genomic Science”, which has the purpose of building genomics capacity at institutions that are not prior or current grantees of the CEGS program. Additional funds are available in FY 2021 for this purpose.
To encourage these applications for funding in FY 2021, NHGRI is adding an additional receipt date (November 20, 2020) to the existing CEGS PAR-19-204 . As described in NOT-HG-20-013, which modified the application Selection Criteria, we emphasize our interest in applications from institutions that are not prior or current grantees of the CEGS program. The CEGS program will still consider high-quality applications from all eligible institutions listed in PAR-19-204.
Key Dates
Currently Reads:
Posted Date: February 28, 2019
Open Date (Earliest Submission Date): April 20, 2019
Letter of Intent Due Date(s) While Letters of Intent are normally requested 30 days before the due date, for this FOA LOIs are due 60 days prior to the application due date
Application Due Date(s) May 20, 2019; March 26, 2020, May 18, 2020; May 20, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s): Not applicable.
Scientific Merit Review: Standard dates apply
Advisory Council Review: January 2020, January 2021, January 2022
Earliest Start Date: Standard dates apply
Expiration Date: May 21, 2021
Due Dates for E.O. 12372: Not Applicable
Modified to Read:
Posted Date: February 28, 2019
Open Date (Earliest Submission Date): April 20, 2019
Letter of Intent Due Date(s) Letters of Intent are normally requested 30 days before the due date, for this FOA we request letters of intent further in advance (60 days) if possible.
Application Due Date(s) May 20, 2019; March 26, 2020; May 18, 2020; November 20, 2020; May 20, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s): Not applicable.
Scientific Merit Review: July 2020 for applications submitted for the March 26, 2020 deadline; November, 2020 for the applications submitted for the May 20, 2020 deadline; March 2021 for applications submitted for the November 20, 2020 deadline; November 2021 for applications submitted for the May 20, 2021 deadline.
Advisory Council Review: January 2020, October 2020, January 2021, May 2021, January 2022
Earliest Start Date: Standard dates apply
Expiration Date: May 21, 2021
Due Dates for E.O. 12372: Not Applicable
All other aspects of PAR-19-204, as modified by NOT-HG-20-013, remain unchanged.
Adam Felsenfeld, Ph.D.
Division of Genome Sciences
National Human Genome Research
Telephone: 301-480-2269
Email: [email protected]